Protective effects of memantine and epicatechin on catechol-induced toxicity on Müller cells in vitro

Saffar Mansoor1, Navin Gupta, Georgia Luczy-Bachman

  • 1Department of Ophthalmology, School of Medicine, University of California, Irvine, United States.

Toxicology
|March 30, 2010
PubMed

Insights

Cigarette smoke component catechol harms Müller cells, impacting viability and mitochondrial function. Memantine and epicatechin offer partial protection against these toxic effects, potentially aiding retinal degenerative disorders.

Area of Science:

  • Ophthalmology
  • Cell Biology
  • Toxicology

Background:

  • Müller cells are crucial for retinal health and function.
  • Catechol, a cigarette smoke component, is implicated in cellular damage.
  • Retinal degenerative disorders like AMD involve Müller cell dysfunction.

Purpose of the Study:

  • To evaluate the in vitro toxic effects of catechol on Müller cells (MIO-M1).
  • To investigate the potential of memantine and epicatechin to reverse catechol-induced toxicity.
  • To explore the mechanisms underlying catechol's cytotoxic effects on Müller cells.

Main Methods:

  • MIO-M1 cells were exposed to varying catechol concentrations.
  • Cell viability, caspase-3/7 activity, ROS/RNS production, mitochondrial membrane potential (DeltaPsim), and intracellular ATP content were measured.
  • Effects of pre-treatment with memantine and epicatechin were assessed.

Main Results:

  • Catechol exposure significantly decreased MIO-M1 cell viability and ATP levels, while increasing caspase-3/7 activity and ROS/RNS production.
  • Catechol also reduced mitochondrial membrane potential.
  • Memantine and epicatechin pre-treatment partially reversed catechol's detrimental effects on cell viability, caspase activity, ROS/RNS, DeltaPsim, and ATP levels.

Conclusions:

  • Catechol exerts toxic effects on Müller cells, impairing viability and mitochondrial function.
  • Memantine and epicatechin demonstrate protective potential against catechol-induced Müller cell damage.
  • These findings suggest potential therapeutic strategies for retinal degenerative diseases involving Müller cell degeneration.

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...